1. Baserga R (2005) The insulin-like growth factor-I receptor as a target for cancer therapy. Expert Opin Ther Targets 9:753–768
2. Bhatnagar RS, Rapaka SSR, Liu TZ, Wolfe SM (1972) Hydralazine-induced disturbances in collagen biosynthesis. Biochim Biophys Acta 271:125–132
3. Carmichael J, Degraff W, Gazdar A, Minna J, Mitchell J (1987) Evaluation of a tetrazolinum-based semiautomated colorimetric assay: assessment of chemosensitivity testing. Cancer Res 47:936–942
4. Chinard FP (1952) Photometric estimation of proline and ornithine. J Biol Chem 199:91–95
5. De la Cruz-Hernández E, Perez-Plasencia C, Pérez-Cardenas E, Gonzalez-Fierro A, Trejo-Becerril C, Chávez-Blanco A, Taja-Chayeb L, Vidal S, Gutiérrez O, Dominguez GI, Trujillo JE, Duenas-González A (2011) Transcriptional changes induced by epigenetic therapy with hydralazine and magnesium valproate in cervical carcinoma. Oncol Rep 25:399–407